BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the JMP Securities Life Sciences Conference, June 16, 2022 with a presentation at 2:00 p.m. ET in New … [Read more…]
Following Additional Data Submission to FDA Demonstrating ORR Superiority Over Ibrutinib As Determined by IRC, PDUFA Goal Date Extended to January 20, 2023 to Allow Time for Review CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to … [Read more…]
Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ALS approved in Canada since 2018 ALBRIOZA (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments In a clinical trial, ALBRIOZA … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Anesthesia and Respiratory Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. The report on the global anesthesia and respiratory devices market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Orphan Diseases Partnering 2010-2022: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering. The Global Orphan Diseases Partnering 2010-2022 report provides comprehensive access to available deals and contract documents for over 280 orphan diseases deals signed between the world’s pharmaceutical and biotechnology companies since 2010. Trends in Orphan Diseases … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Biologic Therapies for Wound Care: Technologies and Global Markets” report has been added to ResearchAndMarkets.com’s offering. This report studies the global market for wound care biologics. It describes different types of wound care biologics, including cellular and/or tissue-based products (CTPs), skin substitutes and topical agents, and their current and historical market revenues. Wound … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2015-2022” report has been added to ResearchAndMarkets.com’s offering. The Cancer Monoclonal Antibody Partnering Terms & Agreements report provides comprehensive access to available deals and contract documents for over 600 cancer monoclonal antibody deals entered into by the worlds leading healthcare companies. This report provides details … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Ophthalmics Partnering 2014-2022: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering. The Global Ophthalmics Partnering 2014-2022 report provides comprehensive access to available deals and contract documents for over 550 ophthalmics deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Ophthalmics partnering deals Financial deal … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “2021 Healthcare Research Review” report has been added to ResearchAndMarkets.com’s offering. This Research Review is a collection of highlights from several healthcare market research reports that were published in 2019. This review was compiled with an intent of providing a sampling of the type of market information, guidance, and analysis, that have been … [Read more…]
CAMBRIDGE, England–(BUSINESS WIRE)–EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the appointment of Colin McCracken as Chief Executive Officer with immediate effect. Colin’s appointment will support the next phase of the Company’s development and the commercialisation of its semiconductor-based DNA synthesis platform. Colin brings over 20 years’ experience … [Read more…]
